US5260478.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

US5260478.Pdf |||||||||||||| USOO5260478A United States Patent (19) 11 Patent Number: 5,260,478 Bacon et al. (45) Date of Patent: Nov. 9, 1993 (54) IODINATED AROYLOXY CARBOXAMIDES 57) ABSTRACT 75 Inventors: Edward R. Bacon, East Greenbush; Compounds having the structure Sol J. Daum, Albany, both of N.Y.; Carl R. Illig, Phoenixville, Pa. O R1 R3 O R5 / 73 Assignee: Sterling Winthrop Inc., New York, (z)-c-o-c-e-cc-N R2 R. Yr 21 Appl. No.: 986,646 wherein (Z-)-COO is the residue of an iodinated aromatic 22 Filed: Dec. 8, 1992 acid; n is an integer from 0 to 20; 51) Int. Cl. .............................................. C07C 69/76 R and R2 are independently H, alkyl, fluoroalkyl, 52 U.S. Cl. ......................................... 560/110; 424/5 cycloalkyl, aryl, aralkyl, alkoxy or aryloxy; 58 Field of Search ............................ 560/110; 424/5; R3 and R4 are independently a substituent as defined 514/535, 532 for R1 and R2 above, halogen, hydroxy or acyl amino; (56) References Cited and R and R6 are independently H, alkyl, cycloalkyl, U.S. PATENT DOCUMENTS aryl, aralkyl, alkoxy, alkoxyalkyl, or acetamidoal 5,055.45. 10/1991 Krantz et al. ....................... 560/110 kyl; or R5 and R6, taken together with the nitrogen atom FOREIGN PATENT DOCUMENTS to which they are attached, represent a 4 to 7-mem 30385.98 5/1982 Fed. Rep. of Germany . bered nitrogen containing ring, are useful as con 112915.4 6/1986 Japan . trast agents in x-ray imaging compositions and methods. Primary Examiner-Paul J. Killos Attorney. Agent, or Firm-William J. Davis 8 Claims, No Drawings 5,260,478 1. 2 IODINATED AROYLOXY CARBOXAMIDES O R. R. O. RS (I) II / FIELD OF INVENTION (zy-C-O-c-e-cc-N This invention relates to iodinated aroyloxy carbox R2 R4 Yrs amides which are particularly useful as contrast agents for x-ray imaging. wherein (Z-)-COO is the residue of an iodinated aromatic BACKGROUND OF THE INVENTION acid; O n is an integer from 0 to 20; X-ray imaging is a well known and extremely valu R1 and R2 are independently H, alkyl, fluoroalkyl, able tool for the early detection and diagnosis of various cycloalkyl, aryl, aralkyl, alkoxy or aryloxy; disease states in the human body. The use of contrast R3 and Rare independently a substituent as defined agents for image enhancement in medical x-ray imaging for R and R2 above, halogen, hydroxy or acyl procedures is widespread. An excellent background on 15 anino; iodinated and other contrast agents for medical imaging and R5 and R6 are independently H, alkyl, cycloalkyl, aryl, aralkyl, alkoxy, alkoxyalkyl, or acetamidoal is provided by D. P. Swanson et al., Pharmaceuticals in kyl; Medical Imaging, 1990, MacMillan Publishing Com or R5 and R6, taken together with the nitrogen atom pany. 20 to which they are attached, represent a 4 to 7-mem Various soluble and water insoluble iodinated amides bered nitrogen containing ring. and esters have been used as x-ray contrast agents. For This invention further provides an x-ray contrast example, U.S. Pat. No. 3,097,228 describes derivatives of 2,4,6-triiodobenzoyloxyalkanoic acids having the composition comprising the above-described com 25 pound and a method for medical X-ray diagnostic imag Structure ing which comprises administering to the body of a mammal a contrast effective amount of the above described x-ray contrast composition. foort It is an advantageous feature of this invention that novel compounds are provided which find particular I foohRI utility as x-ray contrast agents. It is another advantageous feature of this invention that compounds are provided having appropriate solu R NHR bility profiles and improved enzymatic degradability. 35 DESCRIPTION OF PREFERREED EMBODEMENTS wherein R is H or lower alkyl, R2 is H or alkanoyl, R3 In structural formula I above, (Z-)-COO is the resi is H or alkanoylamino, and R is lower alkyl. However, due of an iodinated aromatic acid. The iodinated aro there is no suggestion of a carboxamide group linked to 40 matic acid can comprise one, two, three or more iodine an ester group on an iodinated aromatic ring. atoms per molecule. Preferred species contain at least U.S. Pat. No. 4,328,202 describes ionic 5-C-sub two, and more preferably, at least three iodine atoms stituted 2,4,6-triiodoisophthalic acid derivatives as x-ray per molecule. The iodinated compounds can contain contrast agents, but does not suggest a carboxamide substituents which do not deleteriously effect the con group linked to an ester group on an iodinated aromatic 45 trast enhancing capability of the compound. acid. Illustrative examples of suitable aromatic acids in U.S. Pat. No. 4,364,921 describes triiodinated iso clude diatrizoic acid, phthalic acid diamides as nonionic X-ray contrast media, metrizoic acid, but does not suggest a carboxamide group linked to an 50 urokonic acid, ester group on an iodinated aromatic ring. iothalamic acid, EP-A 498,482 describes nanoparticulate x-ray con trimesic acid, trast compositions which have proven to be extremely ioxaglic acid (hexabrix), useful in medical imaging. However, particulate con ioxitalamic acid, trast agents in certain in vivo applications can exhibit 55 tetraiodoterephthalic acid, less than fully satisfactory enzymatic degradation, e.g., iodipamide, and the like. in plasma and blood. In preferred embodiments, (Z-)-COO is the residue of a It would be desirable to provide compounds for use substituted triiodobenzoic acid such as an acyl, carba as x-ray contrast agents having improved enzymatic myl, and/or acylamino substituted triiodobenzoic acid. R1 and R2 independently represent H; substituted or degradability and appropriate solubility profiles. unsubstituted, linear or branched alkyl, preferably con SUMMARY OF THE INVENTION taining from 1 to 20, more preferably 1 to 8 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, We have discovered and prepared novel iodinated pentyl, hexyl and the like; fluoroalkyl, preferably con aroyloxy carboxamides which are useful as contrast 65 taining from 1 to 3 fluorine atoms, the alkyl portion of agents in X-ray contrast compositions. which is as described for R1 above; cycloalkyl, prefera More specifically, in accordance with this invention, bly containing from 3 to 8 carbon atoms such as cyclo there are provided compounds having the structure propyl and cyclobutyl; aryl, preferably containing from 5,260,478 3 4. 6 to 10 carbon atoms, such as phenyl and naphthyl; aralkyl, preferably containing from 7 to 12 carbon R. R. O R atoms, such as benzyl; alkoxy, the alkyl portion of / which contains from 1 to 20 carbon atoms as described X-c-e-cc-N N above; or aryloxy, the aryl portion of which preferably R2 R4 R6 contains from 6 to 10 carbon atoms as described above. R3 and R independently represent a substituent as wherein X is a leaving group and Rl-R6 are as defined defined for R above, halogen, such as chlorine or bro above. Suitable leaving groups include halogen, such as mine, hydroxy, or acylamino, i.e., a Br, I and Cl, sulfonyloxy, such as methanesulfonyloxy 10 and toluenesulfonyloxy. When X = Cl, it has been found O R7 that the addition of NaI can facilitate the reaction. The 7 carboxylates of iodinated aromatic acids and functional -C-N ized amides useful as the starting materials in the prepa Yrs ration of the compounds of this invention are known 15 compounds and/or can be prepared by techniques group wherein R7 and R8 are as defined for R5 below. known in the art. For example, suitable amides include However, reactive substituents such as halogen are not commercially available bronoacetamide and chlo preferred on the carbon atom adjacent to the amide roacetamide derivatives as exemplified below. A gen carbonyi. eral reaction scheme is as follows: Rhu 5 and R6 independently represent H, alkyl as 20 defined for R above; cycloalkyl as defined for Rl R. R3 O R5 above; aryl as defined for R above, aralkyl as defined E / for R above; alkoxy as defined for R1 above; alkoxyal (Z-COO -- X-C-C-C-N -GI kyl, the alkyl portions of which are as defined for R l, N above; acetamidoalkyl, i.e., 25 The reaction can take place between - 78° C. and O 100 C. For convenience, the reaction can take place at -NH-C-alkyl ambient temperature. 30 For convenience, the reaction can take place at ambi wherein alkyl is as defined for R above; or R5 and R6, ent pressure, however, higher and lower pressures are taken together with the nitrogen atom to which they are contemplated. attached, represent a 4 to 7 membered saturated or The following are specific illustrative examples of unsaturated nitrogen containing ring such as piperidyl, preferred compounds of this invention that have been piperizinyl, pyrrolidinyl and the like. 35 prepared: The alkyl, cycloalkyl, aryl, aralkyl and alkoxy groups 2-amino-2-oxoethyl 3,5-bis(acetylamino)-2,4,6-trii and the nitrogen containing ring in structure I above odobenzoate (WIN 65,540), can be unsubstituted or substituted with various substit 2-ethylamino-2-oxoethyl 3,5-bis(acetylamino)-2,4,6-trii uents which do not adversely affect the stability or odobenzoate (WIN 65,312), efficacy of the compounds as x-ray contrast agents such 40 2-diethylamino-2-oxoethyl 3,5-bis(acetylamino)-2,4,6- as alkyl, cycloalkyl, aryl, aralkyl, alkoxy, hydroxy, triiodobenzoate (WIN 67,499), acyloxy, halogen, such as chlorine, bromine and iodine, 2-dibutylamino-2-oxoethyl 3,5-bis(acetylamino)-2,4,6- acylamino, carboalkoxy, carbamyl and the like. How triiodobenzoate (WIN 67,774), ever, reactive substituents such as halogen, hydroxy and 2-diisopropylamino-2-oxoethyl 3,5-bis(acetylamino)- acylamino are not preferred on the carbon atoms, if 45 2,4,6-triiodobenzoate (WIN 67,901), present in R5 and R6 adjacent to the amide nitrogen.
Recommended publications
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
    FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: Active Moiety Name “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4.942,231 Mertens 45 Date of Patent: Jul
    United States Patent (19) 11 Patent Number: 4.942,231 Mertens 45 Date of Patent: Jul. 17, 1990 (54) METHOD OF PREPARING A CHLORINATED, BROMINATED, FOREIGN PATENT DOCUMENTS RADIO-BROMINATED, IODINATED 0011858 6/1980 European Pat. Off. AND/OR RADIOODINATED AROMATIC Primary Examiner-David B. Springer OR HETEROAROMATIC COMPOUND Attorney, Agent, or Firm-Bernard, Rothwell & Brown 75 Inventor: John Mertens, Brussels, Belgium 57 ABSTRACT 73 Assignee: Mallinckrodt, Inc., St. Louis, Mo. The invention relates to a method of preparing a chlori 21 Appl. No.: 735,037 nated, brominated, radiobrominated, iodinated and/or 22 Filed: May 17, 1985 radioiodinated aromatic or heteroaromatic compound, in which the (hetero)aromatic nucleus optionally com (30) Foreign Application Priority Data prises one or more additional substituents, by reacting May 24, 1984 BE Belgium ................................. 899739 the corresponding halogenated or diazonium-sub Jul. 5, 1984 NL Netherlands ......................... 8402138 stituted compound in the presence of a water-soluble 51) Int. Cl..................... C07D 243/14: CO7D 33/36; acid and of copper ions as a catalyst with a likewise CO7B 23/00; CO7C 57/58; C07C 87/28 water-soluble chloride, bromide radiobromide, iodide 52 U.S. C. ..................................... 540/586; 424/1.1; or radio-iodide, in which the reaction is carried out in 54.6/345; 558/388; 562/456; 562/449; 562/574; the presence of one or more reduction agents, which are 570/174; 252/645 stable in acid medium, in a quantity exceeding the quan 58) Field of Search ....................... 562/456, 449, 574; tity of catalyst. The invention also relates to a composi 570/174; 252/645; 424/1.1; 540/586; 54.6/345; tion suitable for diagnostic examination and to a kit for 558/388 the preparation thereof.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • The History of Contrast Media Development in X-Ray Diagnostic Radiology
    MEDICAL PHYSICS INTERNATIONAL Journal, Special Issue, History of Medical Physics 3, 2020 The History of Contrast Media Development in X-Ray Diagnostic Radiology Adrian M K Thomas FRCP FRCR FBIR Canterbury Christ Church University, Canterbury, Kent UK. Abstract: The origins and development of contrast media in X-ray imaging are described. Contrast media were used from the earliest days of medical imaging and a large variety of agents of widely different chemical natures and properties have been used. The use of contrast media, which should perhaps be seen as an unavoidable necessity, have contributed significantly to the understanding of anatomy, physiology and pathology. Keywords: Contrast Media, Pyelography, Angiography, X-ray, Neuroimaging. I. INTRODUCTION Contrast media have been used since the earliest days of radiology [1], and developments in medical imaging have not removed the need for their use as might have been predicted. The history of contrast media is complex and interesting and has recently been reviewed by Christoph de Haën [2] . The need for contrast media was well expressed by the pioneer radiologist Alfred Barclay when he said in 1913 that ‘The x-rays penetrate all substances to a lesser or greater extent, the resistance that is offered to their passage being approximately in direct proportion to the specific gravity’ [3]. Barclay continued by noting that ‘The walls of the alimentary tract do not differ from the rest of the abdominal contents in this respect, and consequently they give no distinctive shadow on the fluorescent screen or radiogram.’ Barclay clearly states the essential problem confronting radiologists. The density differences that are seen on the plain radiographs are those of soft tissue (which is basically water), bony and calcified structures, fatty tissues, and gas.
    [Show full text]
  • Lääkeluettelon Aineet, Liite 1. Ämnena I
    LÄÄKELUETTELON AINEET, LIITE 1. 1 ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Latinskt Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy-aethylprometazinum (N)-Hydroksietyyli-prometatsiini (N)-Hydroxietyl-prometazin (N)-Hydroxyethyl- promethazine 2,4-Dichlorbenzyl-alcoholum 2,4-Diklooribentsyyli-alkoholi 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- aminophenolum 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin
    [Show full text]
  • 3258 Nr 1179
    3258 Nr 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
    [Show full text]
  • WO 2017/222911 A1 (.Pdf)
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/222911 Al 28 December 2017 (28.12.2017) W !P O PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C07K 14/435 (2006.01) C12N 15/11 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US20 17/037702 Published: (22) International Filing Date: — with international search report (Art. 21(3)) 15 June 2017 (15.06.2017) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (25) Filing Language: English amendments (Rule 48.2(h)) (26) Publication Langi English — with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 62/352,471 20 June 2016 (20.06.2016) US (71) Applicant: THE BOARD OF TRUSTEES OF THE LE- LAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386, Stanford, California 94305-2038 (US). (72) Inventors; and (71) Applicants: CHANG, Howard, Y. [US/US]; c/o - Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386, Stanford, California 94305-2038 (US). CHEN, Ye, Grace [US/US]; c/o - Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386, Stanford, California 94305-2038 (US).
    [Show full text]
  • Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini
    Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini CONTRAST AGENTS - FULL LIST OF THE 30 IODINATED PRODUCTS FOR WHICH REPORTS HAVE BEEN SENT OVER THE FIRST 40 YEARS OF THE WHO PHARMACOVIGILANCE SYSTEM, SUBDIVIDED INTO TWO 20-YEAR PERIODS. FOURTH WHO-ITA/ITA-OMS 2010-2011 CONTRIBUTION ON THE 30 BASIC AGGREGATED WHO SYSTEM-ORGAN CLASS DISORDERS (SOCDs), AND SUSPECTED+ ADVERSE REACTIONS AND EVENT PREFERRED NAMES (SADRs+) Dan Bradu and Luigi Rossini* Servizio Nazionale collaborativo WHO-ITA/ITA-OMS, Universita’ Politecnica delle Marche e Progetto di Farmacotossicovigilanza pre-, post-marketing, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary We have examined the PR-22 2010 data set, which includes 155,164 accepted SADRs associated with 30 iodinated contrast agents in use in the Countries participating in the WHO Pharmacovigilance Programme. The SADRs encompass 40 years, from 1968 to 2010, divided into two 20 year periods (1968-1989 and 1990-2010). The data, provided by the UMC, have been analysed in the framework of the Matlab software of correlation clustering leading to an objective classification based on the 30 standard WHO-SOCDs and preferred names. As reflected in the Title the first set of analyses regarded ATC-V08A sub-classes A (9 agents; 63,578 reports), B (12; 84,105), and C (8; 7,171). These were examined 701 Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini separately, then the results of the same procedure applied to the full matrix of 30 products and ―876 non empty‖ SADRs, including ATC-V08A sub-class D (1 agent; 310 reports) were displayed in the Appendices.
    [Show full text]
  • A Primer on Parenteral Radiopaque Contrast Agents
    THE UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO Correspondence Continuing Education Courses For Nuclear Pharmacists and Nuclear Medicine Professionals VOLUME X, NUMBER 2 A Primer on Parenteral Radiopaque Contrast Agents By Peter Dawson, BSc, PhD, CPhys, MBBS, FRCP, FRCR University College London Hospitals London, United Kingdom The University of New Mexico Health Sciences Center College of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. Program No. 039-000-02-005-H04. 3.0 Contact Hours or .30 CEUs A Primer on Parenteral Radiopaque Contrast Agents By: Peter Dawson, BSc, PhD, CPhys, MBBS, FRCP, FRCR University College London Hospitals London, United Kingdom Coordinating Editor and Director of Pharmacy Continuing Education William B. Hladik III, MS, RPh, FASHP, FAPhA College of Pharmacy University of New Mexico Health Sciences Center Managing Editor Julliana Newman, ELS Wellman Publishing, Inc. Albuquerque, New Mexico Editorial Board George H. Hinkle, MS, RPh, BCNP, FASHP, FAPhA Jeffrey P. Norenberg, MS, PharmD, BCNP, FASHP Neil A. Petry, MS, RPh, BCNP, FAPhA Laura L. Boles Ponto, PhD, RPh Timothy M. Quinton, PharmD, MS, RPh, BCNP, FAPhA Guest Reviewer Robert L. Siegle, MD Professor and Chairman Department of Radiologic Sciences Drexel University College of Medicine 245 North 15th Street, MailStop 206 Philadelphia, PA 19102-1192 While the advice and information in this publication are believed to be true and accurate at press time, the author(s), editors, or the publisher cannot accept any legal responsibility for any errors or omissions that may be made. The publisher makes no war- ranty, express or implied, with respect to the material contained herein.
    [Show full text]